Bromocriptine reduces steatosis in obese rodent models
Bromocriptine reduces steatosis in obese rodent models
复制标题
DOI：
10.1016/j.jhep.2006.03.019
复制
发表时间：
2006-09-01
影响因子：
25.7
通讯作者：
Moran, Timothy H.
中科院分区：
文献类型：
--
作者：
Davis, Lisa M.;Pei, Zhengtong;Moran, Timothy H.
背景/目的：肥胖是糖耐量减低、脂肪变性和氧化应激的危险因素，这些都是非酒精性脂肪性肝病的特征。溴隐亭可能具有抗肥胖、胰岛素增敏、降脂和抗氧化的特性。因此，我们假设溴隐亭可以改善肥胖啮齿动物模型中非酒精性脂肪性肝病的标志物。方法：我们对遗传性肥胖的肥胖大鼠和饮食诱导的肥胖大鼠进行了随机对照实验，以评估溴隐亭(10 mg/kg)改善非酒精性脂肪肝病的行为和外周减肥作用。结果：溴隐亭治疗的肥胖大鼠和饮食诱导的肥胖大鼠的行为、摄食量减少和运动活动增加。此外，与对照组相比，溴隐亭治疗组、肥胖大鼠和饮食诱导肥胖大鼠的肝脏甘油三酯显著降低，肝脏锰超氧化物歧化酶显著升高。与脂肪对照组相比，服用溴隐亭的Zucker大鼠血糖显著降低，与瘦对照组相比无明显差异。结论：在遗传性肥胖和饮食诱导的肥胖啮齿动物中观察到的顺从行为、糖耐量、肝脏脂肪堆积和线粒体氧化应激的改善表明溴隐亭有望成为治疗非酒精性脂肪性肝病的一种广泛的治疗方法。(C)2006年欧洲肝脏研究协会。爱思唯尔出版，版权所有。
Background/Aims: Obesity is a risk factor for glucose intolerance, steatosis, and oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti-obesity, insulin-sensitizing, lipolytic, and antioxidant properties. We, therefore, hypothesized that bromocriptine would improve markers of nonalcoholic fatty liver disease in obese rodent models.Methods: We performed a randomized, controlled experiment in genetically obese fatty Zucker rats and diet-induced obese rats to assess for behavioral and peripheral anti-obesity actions of bromocriptine (10 mg/kg) that would improve nonalcoholic fatty liver disease.Results: Behaviorally, food intake decreased and locomotor activity increased in bromocriptine-treated fatty Zucker and dietary-induced obese rats. Peripherally, liver triglycerides were significantly reduced and hepatic manganese superoxide dismutase significantly increased in bromocriptine-treat, d fatty Zucker and diet-induced obese rats compared to controls. Blood glucose was significantly lower in bromocriptine-treated Zucker rats compared to fatty controls and was no different than that of lean controls.Conclusions: Improvements in obesigenic behaviors, glucose tolerance, hepatic lipid accumulation, and mitochondrial oxidative stress observed in genetically obese and diet-induced obese rodents indicate that bromocriptine may be promising as a broad-based therapy for nonalcoholic fatty liver disease. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.